Great Point Partners
$424M 13F equity value
49 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Great Point Partners covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| VOR | VOR BIOPHARMA INC | 1,700,000 | $31M | 7.4% |
| ABVX | ABIVAX SA | 204,314 | $27M | 6.4% |
| VERA | VERA THERAPEUTICS INC | 600,836 | $26M | 6.1% |
| ZURA | ZURA BIO LTD | 4,215,930 | $25M | 5.9% |
| ALMS | ALUMIS INC | 856,061 | $24M | 5.7% |
| SLGL | SOL-GEL TECHNOLOGIES LTD | 274,363 | $20M | 4.8% |
| DFTX | DEFINIUM THERAPEUTICS INC | 425,000 | $20M | 4.7% |
| ANNX | ANNEXON INC | 3,500,000 | $20M | 4.7% |
| ORKA | ORUKA THERAPEUTICS INC | 183,330 | $17M | 4.1% |
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 855,813 | $17M | 3.9% |
Track Great Point Partners's 13F portfolio: $424M in reported holdings, 49 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}